Journal
TRENDS IN GENETICS
Volume 38, Issue 9, Pages 920-943Publisher
CELL PRESS
DOI: 10.1016/j.tig.2022.01.007
Keywords
-
Categories
Funding
- International Rett Syndrome Foundation ANGEL grant
- Department of Defense award [W81XWH-19-1-0022]
- National Institutes of Health [R01MH118351]
Ask authors/readers for more resources
This article discusses the treatment of Rett syndrome and other X-linked disorders. By activating the inactive X-chromosome, the root cause of X-linked disorders can be addressed.
The human X-chromosome harbors only 4% of our genome but carries over 20% of genes associated with intellectual disability. Given that they inherit only one X-chromosome, males are more frequently affected by X-linked neurodevelopmental genetic disorders than females. However, despite inheriting two X-chromosomes, females can also be affected because X-chromosome inactivation enables only one of two X-chromosomes to be expressed per cell. For Rett syndrome and similar X-linked disorders affecting females, disease-specific treatments have remained elusive. However, a cure may be found within their own cells because every sick cell carries a healthy copy of the affected gene on the inactive X (Xi). Therefore, selective Xi reactivation may be a viable approach that would address the root cause of various X-linked disorders. Here, we discuss Rett syndrome and compare current approaches in the pharmaceutical pipeline to restore MECP2 function. We then focus on Xi reactivation and review available methods, lessons learned, and future directions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available